Charged amino acid residues of human immunodeficiency virus type 1 nucleocapsid p7 protein involved in RNA packaging and infectivity.
about
Nucleocapsid and matrix protein contributions to selective human immunodeficiency virus type 1 genomic RNA packaging.HIV type 1 Gag as a target for antiviral therapyIdentification of a minimal region of the HIV-1 5'-leader required for RNA dimerization, NC binding, and packagingStructural determinants and mechanism of HIV-1 genome packagingCross- and Co-Packaging of Retroviral RNAs and Their ConsequencesMultiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication.RNA is a structural element in retrovirus particlesEffective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virionsA heterologous, high-affinity RNA ligand for human immunodeficiency virus Gag protein has RNA packaging activityBasic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA.Rescue of multiple viral functions by a second-site suppressor of a human immunodeficiency virus type 1 nucleocapsid mutation.The human immunodeficiency virus type 1 TAR RNA upper stem-loop plays distinct roles in reverse transcription and RNA packaging.Human immunodeficiency virus type 1 virion density is not determined by nucleocapsid basic residuesTranslation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyproteinThe gag domains required for avian retroviral RNA encapsidation determined by using two independent assays.Mutations within four distinct gag proteins are required to restore replication of human immunodeficiency virus type 1 after deletion mutagenesis within the dimerization initiation site.Alteration of zinc-binding residues of simian immunodeficiency virus p8(NC) results in subtle differences in gag processing and virion maturation associated with degradative loss of mutant NC.Context-dependent phenotype of a human immunodeficiency virus type 1 nucleocapsid mutation.Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation.Partial restoration of replication of simian immunodeficiency virus by point mutations in either the dimerization initiation site (DIS) or Gag region after deletion mutagenesis within the DIS.Characterization of Rous sarcoma virus Gag particles assembled in vitro.Functional recognition of the modified human tRNALys3(UUU) anticodon domain by HIV's nucleocapsid protein and a peptide mimic.Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.Redundant roles for nucleocapsid and matrix RNA-binding sequences in human immunodeficiency virus type 1 assembly.Pokeweed antiviral protein increases HIV-1 particle infectivity by activating the cellular mitogen activated protein kinase pathway.cis-Acting elements important for retroviral RNA packaging specificity.RNA incorporation is critical for retroviral particle integrity after cell membrane assembly of Gag complexes.Retrovirus-specific differences in matrix and nucleocapsid protein-nucleic acid interactions: implications for genomic RNA packagingFunctional replacement of nucleocapsid flanking regions by heterologous counterparts with divergent primary sequences: effects of chimeric nucleocapsid on the retroviral replication cycle.Importance of basic residues in binding of rous sarcoma virus nucleocapsid to the RNA packaging signal.Molecular characterization of the HIV-1 gag nucleocapsid gene associated with vertical transmission.Mapping the RNA binding sites for human immunodeficiency virus type-1 gag and NC proteins within the complete HIV-1 and -2 untranslated leader regions.Distinct roles for nucleic acid in in vitro assembly of purified Mason-Pfizer monkey virus CANC proteins.Basic residues in the nucleocapsid domain of Gag are critical for late events of HIV-1 budding.Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant.Quantitative fluorescence resonance energy transfer microscopy analysis of the human immunodeficiency virus type 1 Gag-Gag interaction: relative contributions of the CA and NC domains and membrane binding.Purification of proteins containing zinc finger domains using immobilized metal ion affinity chromatography.Antigenic variation in Giardia lamblia and the host's immune responseA one-pot preparation of N-2-mercaptobenzoyl-amino amides.Role of HIV-1 RNA and protein determinants for the selective packaging of spliced and unspliced viral RNA and host U6 and 7SL RNA in virus particles
P2860
Q24523051-05A093B8-2748-4C21-B539-D2C88F277608Q24614498-B02B1C70-018D-4479-B58A-00865183A8ACQ24622200-1C55A5F0-B008-403D-AE8C-155804B2C05BQ24632055-E35D88F1-E952-4250-8EB4-F06337CB9222Q28066817-9B12F210-68C7-405F-82EC-D70781F4F308Q28343701-6E7F4570-78D8-4FBB-87CE-3DD771026514Q30054778-FFF71F4F-6B4A-4329-B135-67B56EA36113Q33787271-56611217-45F2-4829-BACD-18459C3BC720Q33795610-DA4F6FB3-1754-4B2A-A550-BB622F66A8BFQ33800960-0536745A-EBAA-4C94-9EFE-FA7D8196C63DQ33803814-8394466D-451C-4293-82AD-C5547F091122Q33805882-1605048F-2BC4-4190-951E-2562A9CDE5E6Q33808429-3C962DE4-2662-4252-BCDF-62E51863EB5DQ33814996-F4EF449F-7E31-4CC7-B0E1-E9D09ED2EB3BQ33816490-A8BD0A23-3EC3-4FC6-9B55-B5E1A091A4C6Q33818125-77C88776-E7FE-4D47-A3B5-094FD1E682B6Q33834585-698D2242-5A20-4011-97DF-42D20E773CD5Q33844733-D9E7E0A4-06C2-4FBC-A132-C9DF3D0F2FC3Q33845445-41F1756D-67A2-46AE-9394-F21B2C5BEDFFQ33850330-67EDB57A-C866-4633-A853-FA5688769C81Q33865636-692F2A84-3E75-4DEA-9D31-F0A05DB9B204Q33962718-C13E18E8-6DD2-43C5-833D-93A0E2E676F9Q34012585-4A8DFDE0-C6F5-48D5-A85D-CBB2253FC979Q34123957-86C48E96-8809-4B4D-BB7A-9ED19D21F685Q34260135-0A24725B-7576-4890-8DF0-EB6EEB3A9410Q34338573-BF286C3E-AB85-4E0E-BE54-D6D797CD161BQ34359148-ECE8DB48-7857-4FEA-823B-251746098309Q34384875-C133AB91-8776-4FDA-B621-9750BC66E2DDQ34461837-0FA360BB-68E4-4270-ACB4-6862B9B86ABEQ34469084-D1349856-F63E-46DC-96B1-01908512E718Q34599516-C5AEF5AD-F63D-45CC-9947-6EA339E6D5F9Q34673247-CFEBD477-2887-45D6-9C96-2C937391B716Q34717899-275A0E58-7726-47DB-B0C6-DFB585043DEDQ34741702-80481AB8-90E1-43E5-8BBB-A0258ECB94EFQ34976852-CFDC4964-AC4B-4970-B1C4-7DAB5111367CQ34978433-A57DBE35-F7A4-424E-BA91-EB49BF65B886Q35098815-623D51EB-A77C-4A3D-85CB-5E78E86B3D3DQ35211702-DF63E681-8D7E-4756-9EC1-22210027009BQ35216626-8F5B61D1-40EB-4C28-B812-9E9D17C2E68CQ35468374-690504E0-7F99-485C-91C0-696CAFDC227C
P2860
Charged amino acid residues of human immunodeficiency virus type 1 nucleocapsid p7 protein involved in RNA packaging and infectivity.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Charged amino acid residues of ...... RNA packaging and infectivity.
@ast
Charged amino acid residues of ...... RNA packaging and infectivity.
@en
type
label
Charged amino acid residues of ...... RNA packaging and infectivity.
@ast
Charged amino acid residues of ...... RNA packaging and infectivity.
@en
prefLabel
Charged amino acid residues of ...... RNA packaging and infectivity.
@ast
Charged amino acid residues of ...... RNA packaging and infectivity.
@en
P2093
P2860
P1433
P1476
Charged amino acid residues of ...... RNA packaging and infectivity
@en
P2093
P2860
P304
P407
P577
1996-10-01T00:00:00Z